GlassScriptPhysician profile
Tylan Wayne Magnusson
NPI 1437619517
$2,049.15
in general payments reported to CMS, 2019-2025
33 companies · $1,318 in 2025
The $1,318 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $85.95 · 2023: $200 · 2024: $445 · 2025: $1,318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,458 · Education: $505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,458.26 |
| Education | $504.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $285.89 | 2022-2023 | |
| Incyte Corporation | $208.15 | 2024-2025 | Jakafi |
| Abbvie INC. | $167.76 | 2024-2025 | |
| Pfizer INC. | $161.97 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $131.28 | 2025 | Keytruda, Welireg, Keytruda Qlex |
| Blueprint Medicines Corporation | $124.66 | 2024 | Ayvakit |
| Takeda Pharmaceuticals U.S.A., INC. | $88.46 | 2025 | Ninlaro, Fruzaqla |
| Daiichi Sankyo INC. | $79.17 | 2025 | Enhertu, Datroway |
| Astrazeneca Pharmaceuticals LP | $68.28 | 2025 | Imfinzi, Calquence, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $63.78 | 2025 | Opdivo, Opdualag |
| Novartis Pharmaceuticals Corporation | $63.66 | 2025 | |
| Glaxosmithkline, LLC. | $52.76 | 2025 | Jemperli, Zejula, Ojjaara |
| Geron Corporation | $52.50 | 2025 | Rytelo |
| Regeneron Healthcare Solutions, INC. | $41.92 | 2024-2025 | Libtayo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.12 | 2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $37.81 | 2025 | Rybrevant, Balversa, Erleada |
| Legend Biotech USA INC. | $31.63 | 2025 | Carvykti |
| Eisai INC. | $31.24 | 2025 | |
| Kite Pharma, INC. | $30.79 | 2025 | |
| Astellas Pharma US INC | $30.61 | 2025 | Cresemba |
| Tersera Therapeutics LLC | $27.43 | 2025 | Quzyttir |
| Celgene Corporation | $26.01 | 2025 | Reblozyl |
| Novocure INC. | $23.24 | 2025 | Optune Lua (Novottf-200t) |
| Sumitomo Pharma America, INC. | $22.10 | 2025 | Orgovyx |
| Rigel Pharmaceuticals, INC. | $21.53 | 2025 | Gavreto, Rezlidhia, Tavalisse |
| Genentech USA, INC. | $19.25 | 2025 | Venclexta |
| Emd Serono, INC. | $18.86 | 2025 | |
| Array Biopharma INC | $18.47 | 2025 | Xalkori |
| Fennec Pharmaceuticals, INC. | $18.34 | 2025 | Fyarro |
| Stemline Therapeutics INC. | $17.55 | 2025 | Orserdu |
| Syndax Pharmaceuticals, INC. | $16.33 | 2025 | Revuforj |
| Janssen Scientific Affairs, LLC | $15.69 | 2024 | Rybrevant |
| Alexion Pharmaceuticals, INC. | $13.91 | 2025 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tylan Magnusson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.